Time for Cooperation in Health Economics among the Modelling Community

  title={Time for Cooperation in Health Economics among the Modelling Community},
  author={R. Arnold and S. Ekins},
  • R. Arnold, S. Ekins
  • Published 2012
  • Economics, Medicine
  • PharmacoEconomics
  • 1 Master of Public Health Program, Mount Sinai School of Medicine, Department of Preventive Medicine, New York, New York, USA 2 Arnold Consultancy and Technology LLC, New York, New York, USA 3 Arnold and Marie Schwartz College of Pharmacy, Brooklyn, New York, USA 4 Collaborations in Chemistry, Jenkintown, Pennsylvania, USA 5 Collaborative Drug Discovery, Burlingame, California, USA 6 Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland, USA 7 Department of… CONTINUE READING
    18 Citations

    Figures and Topics from this paper

    Explore Further: Topics Discussed in This Paper

    Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling
    • 3
    • PDF
    Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals
    • 3
    • PDF
    Model Registration: A Call to Action
    • 15
    • PDF
    To model or not to model: lessons from two vaccinations
    • 1
    • PDF
    Ahead of Our Time: Collaboration in Modeling Then and Now
    • 13
    Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis
    • 5


    Drug discovery dilemma and Cura quartet collaboration.
    • 9
    Methods for the economic evaluation of health care programmes
    • 6,569
    • PDF
    Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.
    • M. Weinstein, B. O'brien, +4 authors B. Luce
    • Computer Science, Medicine
    • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
    • 2003
    • 1,058
    • PDF
    Pharmacoeconomics : From Theory to Practice
    • 27
    How Can Cost-Effectiveness Information Help Control Unsustainable Growth in U.S. Health Care Spending?
    • 4
    The pharmaco-economics of peri-operative beta-blocker and statin therapy in South Africa.
    • 14
    To model or not to model: lessons from two vaccinations
    • 1
    • PDF